<DOC>
	<DOC>NCT01181973</DOC>
	<brief_summary>The hypothesis to be tested is that the bioavailability of the new 30-mg vial is similar to that of the current approved 15 -mg vials. In addition, the SC injection using the new 30-mg vial is safe and well-tolerated.</brief_summary>
	<brief_title>Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy males or females between the ages of 21 and 55 years Positive urine drug screen Excessive use of alcohol or nicotinecontaining products Pregnant or nursing females</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Relative bioavailability</keyword>
	<keyword>pegvisomant</keyword>
</DOC>